Kre-Celazine® as a Viable Treatment for Juvenile Rheumatoid/Idiopathic Arthritis A pilot study. Research study accepted for publication by Journal of Medical Food Results of clinical research, which chronicled the use of Kre-Celazine® in the successful treatment of children (7 to 16 years old) afflicted with Juvenile Rheumatoid Arthritis, were accepted for publication later this year by the Journal of Medical Food. Kre-Celazine®—a patent pending compound from All American Pharmaceutical—recently earned Orphan Drug Status from the FDA in 2013. Executive scientist at All American Pharmaceutical and author of the study, Jeff Golini is tentatively planning to present his research at the Federation of American Societies for Experimental Biology (FASEB) ‘Big Sky Montana - Nutrition Sensing and Metabolic Signaling’ conference later this year. Those interested in his scientific research will have an opportunity to discuss it with him at the conference.
Posted on: Thu, 31 Jul 2014 12:55:49 +0000
Trending Topics
Recently Viewed Topics
© 2015